THIS SHARE WILL BE WORTH 3.00 IN 2009

Agreed - appalling day!

Still strongly believe in this share, but obviously can only concur.

Ouch!

Im very tempted to get out now while there is something left.
This is all too familiar!

Nice to see a director, buying. 50,000 @ 58.5p cant be bad.
The price when bought was parallel to the sp buy at that time.

25k is nothing to those guys.
its a sham to bolster some confidence after recent falls.

Transco,

25k is a fair amount of money, (OK obviously to some people it is just a bit of pocket money) but no one is willing to throw this amount at a lost cause.

Gary Watts is a businessman of some considerable experience. I don't think he would invest this amount if he did not believe he was going to get a good return on the investment.

Garry Watts is currently the Chief Executive Officer of SSL International PLC having previously held the position of Finance Director and Managing Director for Europe. He is also a Non-executive Director of the Medicines and Healthcare Products Regulatory Agency (MHRA), where he chairs the Audit and Risk Committee. Previously, he held executive directorships at Celltech Group plc and Medeva plc. He is a Chartered Accountant and was previously a partner with KPMG, leading the UK healthcare and life science practice.

Nice write up in iii by Edmond Jackson. Dated 29.07.07.

Protherics has potential to double.

It's tricky to discern value in a loss-making business with major potential and its shares currently out of favor. In the case of Protherics (PTI), this is no flaky operation launched on the latest fashion: the company is at the cutting edge of critical care and cancer products, with genuinely valuable relationships with major pharmaceutical groups such as AstraZeneca (AZN).

It goes on to talk about frustration of shareholders festering, and also mentions that sentiment is affected due to pre-tax loss will widen from 3.6 million to 17.5 million in its current financial year to end-March 2008.
It also mentions Protherics huge potential and that although a speculative share, its business plan and good steady cash flow.

All in all a good well balanced report.

Due to copywrite, extracts only.

thanks for that greek

Nice update re Prolarix(TM) phase 1 liver cancer study.

Phase 2 liver cancer study to start in early 2008 by Protherics, with Cancer Research UK reporting on phase 1 also early 2008.

As we know these trials take time and can't be rushed. The important thing is that activation was indicated in ALL patients in the phase 1 trial group.

Progressing nicely.

Interim management statement reads very positive.
The future looks good.

Looks like AXA have increased their holdings a tad (31,702 ). Every little helps

Just goes to show how the market in general can drag companies down.

On Thursday Protherics was among the biggest percentage gainers in Thursday's trading among companies with market capitalizations under $500 million. (no doubt due to the AGM and statement). Even allowing for the UK/USA drop.

Then with nothing directly involving Protherics, this occurs.

On Friday Protherics was among the biggest percentage losers in Thursday's trading among companies with market capitalizations under $500 million.

hi geek,

The slide goes on and on.....
There seems to be no good news at all - the buy by that director looks sick right now!
Time to get rid?

Hi Transco,

Not ditching mine as the company is still very sound and cash steady.
As said many times this is not a company for get rich tomorrow, unless of course the Holy Grail of a drug is found, which can always occur with such a company.
To my mind Protherics is a share you obviously keep your eye on, but don't need to review that often.
As confident as ever.

Although I am never one to point out errors re spelling grammar etc, (I'm dyslexic so without a spell checker I would struggle re posting big time), as it's the content of a post that matters to me, your Hi Geek bought a smile to my face. Slip of the finger no doubt!
If only, I am to IT what Pavarotti is to ballet dancing. Anything with more than an on/off switch causes me big problems. As said, not having a dig, just thought it humorous.

Greek. (Wishing I was a computor Geek).

Hi Greek,

I take your point.
I am a geek in every sense of the word as I work in IT.
Sorry..... for giving you a bad name..

The thing I am worried about is the lack of news good or bad ...ASM for example have a constant stream of news --- its never ending. PTI on the other hand say nothing....

Two licensing agreements announced within 2 days. Great news. Looks like the next 24 months, with what PTI have in differing stages of production, trials, could be very productive indeed.

The share price reflects the future and I see more disapointments.
If these developments were encouraging they would be showing up by now.
Sorry but optimism is unfounded.

IMHO......

Why is optimism unfounded. Protherics are going forward at a decent pace. If you look at development's they are proceeding as expected, with the odd minor blip. As with all bio/drug companies products they don't just jump from the research stage, through the trial stage straight to full production.
The sp is tending to reflect that many look on Protherics shares as a short term share which is never has been or will be.
But as your comment mine is also IMHO. Time will tell as they say.

Sorry but a 50% slump in the sp over the last 9 months tell the story.
You cant buck the market check out ASM over the same period and despite setbacks.
If PTI come back to start of year levels I will eat my hat!!!
IMHO...